Clinical Trials Browser

Carcinoma, Squamous Cell × cabozantinib × Clear all

NCT05007613 2025-01-01

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Phase 2 Completed

Gastrointestinal

Carcinoma, Squamous Cell, Esophageal Neoplasms, Neoplasm Metastasis

NCT04230954 2022-06-07

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Phase 2 Terminated

Adenocarcinoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Carcinoma, Adenosquamous